← Back to Screener
Aprea Therapeutics, Inc. Common stock (APRE)
Price$0.91
Favorite Metrics
Price vs S&P 500 (26W)-38.13%
Price vs S&P 500 (4W)23.16%
Market Capitalization$10.80M
All Metrics
Book Value / Share (Quarterly)$1.61
P/TBV (Annual)0.54x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.57
Price vs S&P 500 (YTD)7.91%
Net Profit Margin (TTM)-4409.14%
EPS (TTM)$-1.97
10-Day Avg Trading Volume0.42M
EPS Excl Extra (TTM)$-1.97
EPS (Annual)$-1.93
ROI (Annual)-95.68%
Cash / Share (Quarterly)$1.78
Revenue Growth QoQ (YoY)-98.38%
ROA (Last FY)-79.08%
Revenue Growth TTM (YoY)-80.98%
EBITD / Share (TTM)$-2.01
ROE (5Y Avg)-145.80%
Operating Margin (TTM)-4631.10%
Cash Flow / Share (Annual)$-1.57
P/B Ratio0.82x
P/B Ratio (Quarterly)0.45x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)-13.30x
Net Interest Coverage (TTM)-78.82x
ROA (TTM)-74.35%
EPS Incl Extra (Annual)$-1.93
Current Ratio (Annual)5.63x
Quick Ratio (Quarterly)5.28x
3-Month Avg Trading Volume1.63M
52-Week Price Return-40.32%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.78
P/S Ratio (Annual)37.79x
Asset Turnover (Annual)0.02x
52-Week High$2.22
EPS Excl Extra (Annual)$-1.93
CapEx CAGR (5Y)-12.39%
Tangible BV CAGR (5Y)5.67%
26-Week Price Return-34.15%
Quick Ratio (Annual)5.28x
13-Week Price Return2.50%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.63x
Enterprise Value$-3.8
Asset Turnover (TTM)0.02x
Book Value / Share Growth (5Y)-53.04%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-4409.14%
Cash / Share (Annual)$1.78
3-Month Return Std Dev131.59%
Net Income / Employee (TTM)$-2
ROE (Last FY)-95.68%
Net Interest Coverage (Annual)-23.37x
EPS Basic Excl Extra (Annual)$-1.93
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.97
ROI (TTM)-90.30%
P/S Ratio (TTM)37.79x
Revenue / Share (Annual)$0.04
Tangible BV / Share (Annual)$10.15
Price vs S&P 500 (52W)-70.15%
Year-to-Date Return10.55%
5-Day Price Return28.47%
EPS Normalized (Annual)$-1.93
ROA (5Y Avg)-126.92%
Net Profit Margin (Annual)-4409.14%
Month-to-Date Return23.61%
Cash Flow / Share (TTM)$-3.97
EBITD / Share (Annual)$-2.01
Operating Margin (Annual)-4631.10%
ROI (5Y Avg)-145.80%
EPS Basic Excl Extra (TTM)$-1.97
P/TBV (Quarterly)0.67x
P/B Ratio (Annual)0.45x
Pretax Margin (TTM)-4409.14%
Book Value / Share (Annual)$1.61
Price vs S&P 500 (13W)1.81%
Beta-1.28x
Revenue / Share (TTM)$0.04
ROE (TTM)-90.30%
52-Week Low$0.55
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.22
4.22
4.22
4.22
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
APREAprea Therapeutics, Inc. Common stock | 37.79x | -80.98% | — | — | $0.91 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Aprea Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology therapies based on synthetic lethality. Its lead program, ATRN-119, is a small-molecule ATR inhibitor in clinical development for solid tumors. The company is also advancing APR-1051, an oral WEE1 inhibitor that recently entered clinical trials.